Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumour × Cisplatin × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 461 Squamous Cell Carcinoma of Head and Neck 217 Head and Neck Neoplasms 207 Lung Neoplasms 205 Uterine Cervical Neoplasms 143 Stomach Neoplasms 139 Esophageal Neoplasms 138 Nasopharyngeal Carcinoma 117 Urinary Bladder Neoplasms 97 Neoplasms 94 Esophageal Squamous Cell Carcinoma 92 Small Cell Lung Carcinoma 85 Breast Neoplasms 79 Ovarian Neoplasms 75 Neoplasm Metastasis 69 Pancreatic Neoplasms 66 Cholangiocarcinoma 63 Carcinoma, Squamous Cell 62 Biliary Tract Neoplasms 62 Mesothelioma, Malignant 52 Adenocarcinoma Of Esophagus 44 Carcinoma 43 Recurrence 41 Oropharyngeal Neoplasms 41 Carcinoma, Ovarian Epithelial 41 Parkinson Disease 4, Autosomal Dominant Lewy Body 39 Gallbladder Neoplasms 36 Adenocarcinoma of Lung 35 Lymphoma 33 Carcinoma, Transitional Cell 32

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡